Open AccessLinezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens
Author(s) -
Barbara Jantausch,
Jaime G. Deville,
Stuart P. Adler,
Maria Rayo Morfin,
Pío López,
Barbara Edge-Padbury,
Sharon Naberhuis-Stehouwer,
Jon B. Bruss
Publication year - 2003
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/01.inf.0000086956.45566.55
Subject(s) - linezolid , bacteremia , medicine , vancomycin , pneumonia , hospital acquired pneumonia , antibiotics , staphylococcus aureus , microbiology and biotechnology , biology , bacteria , genetics
Nosocomial infections, particularly hospital-acquired pneumonia (HAP) and bacteremia, are an increasing concern in pediatric hospitals and pediatric intensive care units. Gram-positive pathogens are a leading cause of these infections in children. Linezolid is well-tolerated and as effective as vancomycin in the treatment of these infections in adults.